Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Clinical Cancer Research

• Publication date

  2018-03-29

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-17-1717PMID 29599413PMCID PMC6050085
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rad51 Degradation: Role in Oncolytic Virus—Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma

  2017cited by this paper
• Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

  2017cited by this paper
• Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma

  2017cited by this paper
• Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials.

  2017cited by this paper
• Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.

  2017cited by this paper
• A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma.

  2016cited by this paper
• Axitinib induces senescence-associated cell death and necrosis in glioma cell lines: The proteasome inhibitor, bortezomib, potentiates axitinib-induced cytotoxicity in a p21(Waf/Cip1) dependent manner

  2016cited by this paper
• Oncolytic virus therapy: A new era of cancer treatment at dawn

  2016influential reference
• Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion

  2016influential reference
• Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma

  2016cited by this paper
• Survival in glioblastoma: a review on the impact of treatment modalities

  2016cited by this paper
• Axitinib Has Antiangiogenic and Antitumorigenic Activity in Myxoid Liposarcoma

  2016cited by this paper
• Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.

  2016cited by this paper
• Oncolytic herpes simplex virus interactions with the host immune system.

  2016cited by this paper
• Cancer stem cells in glioblastoma

  2015cited by this paper
• Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy

  2015cited by this paper
• In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells.

  2015cited by this paper
• EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA.

  2015cited by this paper
• Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model

  2015influential reference
• Targeting Hypoxia-Inducible Factor 1&agr; in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment

  2015influential reference
• The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence

  2015cited by this paper
• Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

  2015cited by this paper
• Designing herpes viruses as oncolytics

  2015cited by this paper
• Promising early results for immunotherapy-antiangiogenesis combination.

  2014cited by this paper
• Antiangiogenic Therapy for Glioblastoma: Current Status and Future Prospects

  2014cited by this paper
• Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma

  2014influential reference
• Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine

  2014cited by this paper
• Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models.

  2013cited by this paper
• Reduced Immunosuppressive Properties of Axitinib in Comparison with Other Tyrosine Kinase Inhibitors*

  2013influential reference
• Angiogenesis in glioblastoma.

  2013cited by this paper
• A phase II trial of second‐line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma

  2013cited by this paper
• Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model

  2013influential reference
• Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.

  2013cited by this paper
• Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

  2012influential reference
• Thermal Stability of Fibroblast Growth Factor Protein Is a Determinant Factor in Regulating Self‐Renewal, Differentiation, and Reprogramming in Human Pluripotent Stem Cells

  2012cited by this paper
• Anti-angiogenic gene therapy in the treatment of malignant gliomas.

  2012cited by this paper
• Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model

  2012cited by this paper
• ONCOLYTIC VIROTHERAPY

  2012cited by this paper
• Mechanisms of glioma-associated neovascularization.

  2012cited by this paper
• Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells.

  2012cited by this paper
• A Novel Oncolytic Herpes Simplex Virus that Synergizes with Phosphoinositide 3-kinase/Akt Pathway Inhibitors to Target Glioblastoma Stem Cells

  2011cited by this paper
• Brain tumor stem cells: The cancer stem cell hypothesis writ large

  2010cited by this paper
• Development of a novel mouse glioma model using lentiviral vectors

  2009cited by this paper
• Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.

  2009cited by this paper
• Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.

  2009cited by this paper
• ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays.

  2009cited by this paper
• Oncolytic virotherapy.

  2008cited by this paper
• Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

  2008cited by this paper
• AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.

  2007cited by this paper
• Angiogenesis in brain tumours

  2007cited by this paper
• Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing

  2001influential reference
• Initial interaction of herpes simplex virus with cells is binding to heparan sulfate

  1989cited by this paper

• A novel oncolytic Vaccinia virus armed with IL-12 augments antitumor immune responses leading to durable regression in murine models of lung cancer

  2025cites this paper
• Advancements on the synergistic application of oncolytic viruses and molecularly targeted therapies for the treatment of solid tumors (Review)

  2025cites this paper
• Oncolytic virotherapy: molecular mechanisms, delivery strategies, and translational insights.

  2025cites this paper
• Viral warriors: Unlocking the immune system’s potential with oncolytic viruses in cancer immunotherapy

  2025cites this paper
• Oncolytic Virus Therapies in Malignant Gliomas: Advances and Clinical Trials

  2025cites this paper
• Oncolytic Virotherapy for Glioma: A Bibliometric Roadmap for Multidisciplinary Clinical and Research Strategies

  2025cites this paper
• Anti-neoangiogenic nanodelivery systems: advances in tumor-based and ophthalmic disease research.

  2025cites this paper
• Promoting the therapeutic potential of interleukin-7 (IL-7) by expression in viral vectors

  2025cites this paper
• Current evidence and challenges of multitarget anti-angiogenic agents for glioblastoma: Results from clinical trials

  2025cites this paper
• Targeting Macrophages in Glioblastoma: Current Therapies and Future Directions

  2025cites this paper
• Oncolytic Herpes Simplex Virus Therapy: Latest Advances, Core Challenges, and Future Outlook

  2025cites this paper
• Exploring the potential of oncolytic viral vectors in targeted cancer therapy: advances, challenges and future directions

  2025cites this paper
• Oncolytic HSV and cancer drug interactions: Current clinical status and future directions

  2025cites this paper
• SNX17 knockdown improves post-ischemic angiogenesis via blocking lysosomal dependent VEGFR degradation.

  2025cites this paper
• Angiogenesis in Glioblastoma—Treatment Approaches

  2025cites this paper
• A Review of FDA-Approved Multi-Target Angiogenesis Drugs for Brain Tumor Therapy

  2025cites this paper
• Strategies to Combat Resistance to Anti-angiogenesis Therapies in Cancer: Current Status and Future Prospects.

  2025cites this paper
• Glioblastoma Therapy: Past, Present and Future

  2024cites this paper
• Immunocompetent murine glioblastoma stem-like cell models exhibiting distinct phenotypes

  2024cites this paper
• Interleukin-12 Delivery Strategies and Advances in Tumor Immunotherapy

  2024cites this paper
• N‐Acetyl‐L‐Cysteine (NAC) Blunts Axitinib‐Related Adverse Effects in Preclinical Models of Glioblastoma

  2024cites this paper
• Improvement of current immunotherapies with engineered oncolytic viruses that target cancer stem cells

  2024cites this paper
• Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy?

  2024influential citation
• Integration of Computational Pipeline to Streamline Efficacious Drug Nomination and Biomarker Discovery in Glioblastoma

  2024cites this paper
• The combination therapy of oncolytic virotherapy

  2024cites this paper
• Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival

  2024cites this paper
• Nanosphere pharmacodynamics improves safety of immunostimulatory cytokine therapy

  2024cites this paper
• IFNγ is a central node of cancer immune equilibrium

  2023cites this paper
• Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario

  2023cites this paper
• Fusion peptide is superior to co-expressing subunits for arming oncolytic herpes virus with interleukin 12

  2023cites this paper
• Oncolytic virotherapy: basic principles, recent advances and future directions

  2023cites this paper
• Antiangiogenic Therapy for Malignant Brain Tumors: Does It Still Matter?

  2023cites this paper
• Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells

  2023cites this paper
• Viral Vectors Expressing Interleukin 2 for Cancer Immunotherapy

  2023cites this paper
• Tumor Microenvironment: A Niche for Cancer Stem Cell Immunotherapy

  2023cites this paper
• Teserpaturev/G47Δ: First Approval

  2022cites this paper
• Histone deacetylase inhibitors enhance oncolytic herpes simplex virus therapy for malignant meningioma

  2022cites this paper
• Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways

  2022cites this paper
• The emerging field of oncolytic virus-based cancer immunotherapy.

  2022cites this paper
• Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy

  2022cites this paper
• A phase I/II study of triple-mutated oncolytic herpes virus G47∆ in patients with progressive glioblastoma

  2022cites this paper
• Cancer combination therapies by angiogenesis inhibitors; a comprehensive review

  2022cites this paper
• Emerging systemic delivery strategies of oncolytic viruses: A key step toward cancer immunotherapy

  2022cites this paper
• Pathogenetic Features and Current Management of Glioblastoma

  2021cites this paper
• A vasculature-centric approach to developing novel treatment options for glioblastoma

  2021cites this paper
• Clinically Explored Virus-Based Therapies for the Treatment of Recurrent High-Grade Glioma in Adults

  2021cites this paper
• OV_A_268426 1..27

  2021cites this paper
• Hypoxia Reduction Sensitizes Refractory Cancers to Immunotherapy.

  2021cites this paper
• Targeting the molecular mechanisms of glioma stem cell resistance to chemotherapy

  2021cites this paper
• The Immune Privilege of Cancer Stem Cells: A Key to Understanding Tumor Immune Escape and Therapy Failure

  2021cites this paper
• Combining Oncolytic Viruses and Small Molecule Therapeutics: Mutual Benefits

  2021cites this paper
• Optimal timing of PD-1 blockade in combination with oncolytic virus therapy.

  2021cites this paper
• The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment

  2021cites this paper
• Recent advances in targeting cancer stem cells using oncolytic viruses

  2020cites this paper
• Virus-Based Therapies for the Treatment of Recurrent High-Grade Glioma

  2020cites this paper
• Immunocompetent Mouse Models in the Search for Effective Immunotherapy in Glioblastoma

  2020cites this paper
• Kinase inhibitors with viral oncolysis: Unmasking pharmacoviral approaches for cancer therapy.

  2020cites this paper
• Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma

  2020cites this paper
• Oncolytic Herpes Simplex Virus Encoding IL12 Controls Triple-Negative Breast Cancer Growth and Metastasis

  2020influential citation
• Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy

  2020influential citation
• Immunohistochemistry for Tumor-Infiltrating Immune Cells After Oncolytic Virotherapy.

  2019cites this paper
• Oncolytic Herpes Simplex Virus Immunotherapy for Brain Tumors: Current Pitfalls and Emerging Strategies to Overcome Therapeutic Resistance

  2019cites this paper
• ERK is a Pivotal Player of Chemo-Immune-Resistance in Cancer

  2019cites this paper
• Phosphorylation of NF-κB in Cancer

  2019cites this paper
• Oncolytic herpes simplex virus therapy for malignant glioma: current approaches to successful clinical application

  2019cites this paper
• Multi-parametric flow cytometry staining procedure for analyzing tumor-infiltrating immune cells following oncolytic herpes simplex virus immunotherapy in intracranial glioblastoma

  2019cites this paper
• PDZ-Binding Kinase-Dependent Transcriptional Regulation of CCNB2 Promotes Tumorigenesis and Radio-Resistance in Glioblastoma

  2019cites this paper
• Harnessing the immune system in glioblastoma

  2018cites this paper